Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54
Marc P Bonaca, Robert F Storey, Pierre Theroux, P Gabriel Steg, Deepak L Bhatt, Marc C Cohen, KyungAh Im, Sabina A Murphy, Giulia Magnani, Ton Oude Ophuis, Mikhail Rudah, Alexander Parkhomenko, Daniel Isaza, Gabriel Kamensky, Assen Goudev, Gilles Montalescot, Eva C Jensen, Per Johanson, Eugene Braunwald, Marc S Sabatine, Marc P Bonaca, Robert F Storey, Pierre Theroux, P Gabriel Steg, Deepak L Bhatt, Marc C Cohen, KyungAh Im, Sabina A Murphy, Giulia Magnani, Ton Oude Ophuis, Mikhail Rudah, Alexander Parkhomenko, Daniel Isaza, Gabriel Kamensky, Assen Goudev, Gilles Montalescot, Eva C Jensen, Per Johanson, Eugene Braunwald, Marc S Sabatine
Abstract
Background: Ticagrelor reduces ischemic risk in patients with prior myocardial infarction (MI). It remains unclear whether ischemic risk and the benefits of prolonged P2Y12 inhibition in this population remain consistent over time.
Objectives: The study sought to investigate the pattern of ischemic risk over time and whether the efficacy and safety of ticagrelor were similar early and late after randomization.
Methods: The PEGASUS-TIMI (Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis In Myocardial Infarction) 54 trial randomized patients with prior MI (median 1.7 years prior) to ticagrelor 90 mg, ticagrelor 60 mg, or placebo on a background of aspirin. The rates of cardiovascular (CV) death, MI, and stroke as well as TIMI major bleeding were analyzed at yearly landmarks (years 1, 2, and 3).
Results: A total of 21,162 patients were randomized and followed for 33 months (median), with 28% of patients ≥5 years from MI at trial conclusion. The risk of CV death, MI, or stroke in the placebo arm remained roughly constant over the trial at an ∼3% annualized rate. The benefit of ticagrelor 60 mg was consistent at each subsequent landmark (year 1 hazard ratio [HR]: 0.82; 95% confidence interval [CI]: 0.67 to 0.99; year 2 HR: 0.90; 95% CI: 0.74 to 1.11; and year 3 HR: 0.79; 95% CI: 0.62 to 1.00). TIMI major bleeding was increased with ticagrelor 60 mg at each landmark, but with the greatest hazard in the first year (year 1 HR: 3.22; year 2 HR: 2.07; year 3 HR: 1.65).
Conclusions: Patients with a history of MI remain at persistent high risk for CVD, MI, and stroke as late as 5 years after MI. The efficacy of low-dose ticagrelor is consistent over time with a trend toward less excess bleeding. (Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin [PEGASUS]; NCT01225562).
Keywords: P2Y(12) inhibition; cardiovascular death; ischemic risk; myocardial infarction; secondary prevention; stroke.
Copyright © 2017 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Source: PubMed